Case Report

Phenytoin-induced Toxic Cholestatic Hepatitis in a Patient with Skin Lesions: Case Report

Authors: Yüksel Altuntas, MD, Bülent Öztürk, MD, Levent Erdem, MD, Gürsel Günes, MD, Sema Karul, MD, Sema Uçak, MD, Ahmet Şengül, MD

Abstract

Phenytoin is a highly effective and widely prescribed anticonvulsant agent, but it can be associated with dose-related side effects and hypersensitivity reactions. We present a case of phenytoin-induced cholestatic hepatotoxicity in a 47-year-old woman who had exfoliative dermatitis, an increase in liver enzymes with a cholestatic pattern, and eosinophilia after 25 days of phenytoin therapy. The diagnostic workup showed no other possible causes, and the results of a percutaneous liver biopsy were consistent with drug-induced toxic hepatitis. Within 3 weeks after discontinuing phenytoin therapy, her liver function tests returned to normal values.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Gungor E, Alli N, Comoglu S, Comcuoglu C. Phenytoin hypersensitivity syndrome. Neurol Sci 2001; 22: 261–265.
 
2. de la Serna Higuera C, Gil Grande LA, Barcena Marugan R. Toxic cholestatic hepatitis due to phenytoin [in Spanish]. Gastroenterol Hepatol 1995; 18: 471–473.
 
3. Prosser TR, Lander RD. Phenytoin-induced hypersensitivity reactions. Clin Pharm 1987; 6: 728–734.
 
4. Mullick FG, Ishak KG. Hepatic injury associated with diphenylhydantoin therapy: A clinicopathologic study of 20 cases. Am J Clin Pathol 1980; 74: 442–452.
 
5. Roberts EA, Spielberg SP, Goldbach M, Phillips MJ. Phenobarbital hepatotoxicity in an 8-month-old infant. J Hepatol 1990; 10: 235–239.
 
6. Kahn HD, Faguet GB, Agee JF, Middleton HMIII. Drug-induced liver injury: In vitro demonstration of hypersensitivity to both phenytoin and phenobarbital. Arch Intern Med 1984; 144: 1677–1679.
 
7. Fonseca JC, Azulay DR, Rozembau I, Azulay RD. Hypersensitivity syndrome caused by phenytoin and phenobarbital [in Portuguese]. Med Cutan Ibero Lat Am 1984; 12: 187–192.
 
8. Lee TJ, Carney CN, Lapis JL, Higgins T, Fallon HJ. Diphenylhydantoin-induced hepatic necrosis: A case study. Gastroenterology 1976; 70: 422–424.
 
9. Conger LA Jr, Grabski WJ. Dilantin hypersensitivity reaction. Cutis 1996; 57: 223–226.
 
10. Carro JA, Senior J, Rubio CE, Torres EA. Phenytoin induced fatal hepatic injury. Bol Asoc Med P R 1989; 81: 359–360.
 
11. Campbell CB, McGuffie C, Weedon AP, Powell LW. Cholestatic liver disease associated with diphenylhydantoin therapy: Possible pathogenic importance of altered bile salt metabolism. Am J Dig Dis 1977; 22: 255–262.
 
12. Spielberg SP, Gordon GB, Blake DA, Goldstein DA, Herlong HF. Predisposition to phenytoin hepatotoxicity assessed in vitro. N Engl J Med 1981; 305: 722–727.
 
13. Larrey D, Pageaux GP. Genetic predisposition to drug-induced hepatotoxicity. J Hepatol 1997; 26 (Suppl 2): 12–21.
 
14. Gram L, Bentsen KD. Hepatic toxicity of antiepileptic drugs: A review. Acta Neurol Scand Suppl 1983; 97: 81–90.
 
15. Sherertz EF, Jegasothy BV, Lazarus GS. Phenytoin hypersensitivity reaction presenting with toxic epidermal necrolysis and severe hepatitis: Report of a patient treated with corticosteroid “pulse therapy.” J Am Acad Dermatol 1985; 12: 178–181.